Thanks, couldn't get in on my device, could just see the slides. So the 3-71 Part B is still recruiting. It's a small trial, but it is single-site so not necessarily slow. Nice to hear about PD getting underway soon.
Without longitudinal charts for the OLE endpoints, it leaves open the possibility that there was no absolute improvement in trajectory for early cohort's ADL, just relative separation between cohorts. Let's see if we get a clearer picture at the PD/AD conf, though I suspect it's not coming.
(For anyone puzzled, it's like being told you have "stat-sig AUC" but aren't shown the curve; the curve apparently bows back to control. Or we had "stat-sig odds risk" but aren't shown the responders #'s; the responders numbers themselves aren't significant. Lack of transparency is not good to investors or clinicians.)
Market Data 
Markets 
AI
